Aida Guseykhanovna Gadzhigoroeva

Aida Guseykhanovna Gadzhigoroeva

Auto-generated profile, based on publicly available information

Aida Guseykhanovna Gadzhigoroeva

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology; Peoples’ Friendship University of Russia named after Patrice Lumumba

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Journal of Photochemistry and Photobiology B: Biology
Verified
Journal Article
Closed access
MFM.V. Fedorkova
M.V. Fedorkova
NSN.V. Smolina
N.V. Smolina
EMElena Mikhalchik
Elena Mikhalchik
NBNadezhda Georgievna Balabushevich
Nadezhda Georgievna Balabushevich
GIG.A. Ibragimova
G.A. Ibragimova
GDG.E. Dobretsov
G.E. Dobretsov

7 May 2018 in Skin Appendage Disorders
Verified
Journal Article
Open access
PDF file
RTRalph Michel Trüeb
Ralph Michel Trüeb
SVSergio Vano-Galvan
Sergio Vano-Galvan
DKDaisy Kopera
Daisy Kopera
VJVicky M.L. Jolliffe
Vicky M.L. Jolliffe
DIDemetrios Ioannides
Demetrios Ioannides
CTChuchai Tanglertsampan
Chuchai Tanglertsampan
Few dermatologic problems carry as much emotional overtones as the complaint of hair loss. The best way to alleviate the distress related to hair loss is to effectively treat it. In fact, one of the oldest medical professions is the Egyptian physician who specialized on diseases of the head. And yet, from ancient Egypt down to modern times, human hair has been the object of superstition and mystery. Remarkably and despite the genuine advances in effective medical treatments, hair cosmetics, and surgical procedures, phony hair loss solutions continue to be marketed with an amazing success. In 1860, a quasi-scientific interest in hair loss and hair care originated in a London barbershop and became known as trichology, with the Institute of Trichologists being founded. Other corporations successively followed internationally, but it was only in 2010 that the term dermatotrichologist was proposed for board-certified dermatologists dealing with the scientific study of the hair and scalp, in contrast to the trichologist who is rather associated with laity and cosmetics than with medical professionalism, or – worse – offers opportunities to possible imposters with a primary commercial interest. The new term “trichiatrist” is proposed, literally meaning the “medical treatment of the hair,” to designate the strictly medical professional dealing with the hair and scalp in health and disease. Trichiatrists differ from trichologists by virtue of being physicians. The quality and stringency of their graduate medical training is identical to that of other physicians.

20 August 2019 in Skin Appendage Disorders
Verified
Journal Article
Open access
PDF file
RTRalph M. Trüeb
Ralph M. Trüeb
VJVicky M.L. Jolliffe
Vicky M.L. Jolliffe
ARAntonia Fellas Régnier
Antonia Fellas Régnier
HRHudson Dutra Rezende
Hudson Dutra Rezende
SVSergio Vañó-Galván
Sergio Vañó-Galván
CTChuchai Tanglertsampan
Chuchai Tanglertsampan
Evidence-based medicine (EBM) aims for the ideal that healthcare professionals make conscientious, explicit, and judicious use of the best available evidence gained from the scientific method to clinical decision-making. It seeks to assess the strength of the evidence for benefits of diagnostic tests and treatments, using techniques from science, engineering, and statistics, such as the systematic review of medical literature, meta-analysis, risk-benefit analysis, and randomized controlled trials. The limited success rate of EBM therapies suggests that the complex nature of hair loss may be inadequately served by the present levels of evidence, and that physicians treating hair loss may have fallen short of adequately researching a robust evidence to underpin their practices. Against this backdrop, the concept of precision medicine (PM) is evolving. PM refers to the customization of medical care to the patient’s individual characteristics based on the patient’s genetic background and other molecular or cellular analysis, while classifying patients into subpopulations that differ in their susceptibility to a particular medical condition, in the biology or prognosis of those medical conditions, or in their response to a specific treatment. With the advances in hair research, the powerful tools of molecular biology and genetics, and innovative technologies, we have the robust scientific data and tools to adapt the concept of PM to the practice of trichiatry. Finally, databases pertaining to the development and efficacy of PM must be analyzed and be used to form the basis of evidence-based personalized trichiatry.

23 July 2025 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
NMNekma Meah
Nekma Meah
JLJane Li
Jane Li
DWDmitri Wall
Dmitri Wall
KYKatherine York
Katherine York
BBBevin Bhoyrul
Bevin Bhoyrul
RSRodney Sinclair
Rodney Sinclair
Background: As the incidence of frontal fibrosing alopecia (FFA) continues to rise, there is a need for an optimal treatment algorithm for FFA. Objectives: To produce an international consensus statement on the treatment modalities and prognostic indicators of FFA. Methods: Sixty‐nine hair experts from six continents were invited to participate in a three‐round Delphi process. The final stage was held as a virtual meeting facilitated via Zoom. The consensus threshold was set at ≥66%. Results: Of 365 questions, expert consensus was achieved in 204 (56%) questions following completion of the three rounds. Three additional questions were included at the final meeting. The category with the strongest consensus agreement was disease monitoring (9; 100%). Questions pertaining to physical therapies achieved the least category consensus (15; 40%), followed by systemic therapy (45; 43%). Limitations: The study lacked sufficient representation from Africa and South America. Conclusions: SOFFIA highlights areas of agreement and disagreement among experts. Robust research is warranted to provide evidence‐based treatment recommendations.

16 March 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
TTT. V. Tsimbalenko
T. V. Tsimbalenko
AGA. G. Gadzhigoroeva
A. G. Gadzhigoroeva
NPN. N. Potekaev
N. N. Potekaev
GTG. P. Tereshchenko
G. P. Tereshchenko
EMElena Mikhalchik
Elena Mikhalchik
Introduction. Androgenetic alopecia (AGA) is the most common type of alopecia, characterized by diffuse progressive thinning of the hair in the fronto-parietal area in patients with a genetic predisposition. Topical minoxidil remains the primary pharmacological treatment for AGA both in men and women. The efficacy in hair regrowth is reported to be between 40 and 50%.Aim. To evaluate prognostic factors of minoxidil response in AGA patients.Matherials and methods. The prospective open study was carried out. Thirty participants with AGA were enrolled and completed the study (twenty one women I–II Ludwig stage and nine men I–III Hamilton – Norwood stage). Primary outcomes consisted of measuring of hair density, telogen hair rate, the percentage of vellus hairs and hair diameter at baseline and repeated at 4 months. The SULT1A1 enzyme activity and the concentration of ATP in plucked hairs were measured at baseline. Patients were treated with 5% topical minoxidil applying daily for 4 months. In order to investigate prognostic factors in groups of responders and non-responders to minoxidil treatment these measured morphometric and biochemical characteristics were assessed.Results. After 4 months of treatment 77% of patients demonstrated hair regrowth and improvement of hair density, hair diameter and decrease of vellus hairs level. The SULT1A1 enzyme activity (p = 0.0008), the concentration of ATP (p = 0.004) in plucked hairs and baseline total hair density (p = 0.01) was significantly lower in group of non-responders compared to group of responders. The study demonstrated strong positive correlation between SULT1A1 enzyme activity and increase of total hair density (r = 0.7, р = 0.00002); moderate positive correlation was founded between concentration of ATP and increase of total hair density (r = 0.6, р = 0.0004).Conclusion. The negative prognostic factors for minoxidil treatment of AGA include SULT1A1 enzyme activity, concentration of ATP in plucked hairs and low total hair density at baseline.

29 August 2025 in Kuban Scientific Medical Bulletin
Verified
Journal Article
Open access
PDF file
NPN. N. Potekaev
N. N. Potekaev
GTG. P. Tereshchenko
G. P. Tereshchenko
OZO. V. Zhukova
O. V. Zhukova
AGA. G. Gadzhigoroeva
A. G. Gadzhigoroeva
RKR. A. Khanferyan
R. A. Khanferyan
Background. Alopecia areata is an autoimmune disease affecting hair follicles that is frequently associated with atopic diseases. Studies on cytokine profiles in the context of atopic comorbidities help to identify the key immune mechanisms and specific immunophenotypes. The present study aims to identify immune differences in alopecia areata depending on the atopic status.Objective. To assess the serum levels of the main proinflammatory and regulatory cytokines in patients with alopecia areata, taking the presence of atopic diseases and the severity of the process into account.Methods. An observational cohort cross-sectional study was conducted at the Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of the Moscow City Health Department. The study included 44 alopecia areata patients aged 5–17 years, who were divided into two groups: 1) patients without atopy (n = 17); 2) patients with concomitant atopic diseases (n = 27). The severity of alopecia areata was graded using the Severity of Alopecia Tool (SALT). Cytokine concentration was studied via a multiplex assay (Luminex 200, ProcartaPlex Human Cytokine&Chemokine Panel 1A, 34plex). Of the 34 target parameters, granulocyte-macrophage colony-stimulating factor, interleukin-1β, and interleukin-15 were excluded from analysis due to the lack of detection in ≥20 participants. The remaining 31 parameters were compared between the groups and with the comparable healthy control group (n = 30). The correlation between the serum cytokine levels and alopecia severity was analyzed. The obtained data were statistically processed using Statistica 10.0 (StatSoft, USA) and Microsoft Excel 2016 (Microsoft Corporation, USA). The statistical significance level is α = 0.05. In order to estimate the correlation coefficient (r) and its statistical significance (p), Spearman’s coefficient was used. SCImagoGraphica software (SCImago LAB, Spain) was used for the graphic representation of the obtained results.Results. Differences between Groups 1–2 and the control group were found for 18 cytokines. Group 2 patients (with atopy) exhibited differences from the control group (p < 0.005) in the distribution of levels of all Type 2 cytokines, Type 1 cytokines (interleukin-2, interleukin-12, and tumor necrosis factor alpha and beta), and T helper 17 cytokines (interleukins 21, 22, 23, and 27), except for interleukin-17A. In Group 1 (without atopy), interleukin-4, interleukin-9, and eotaxin levels did not differ from those in the control group, while the level of interleukin-17A was elevated (p = 0.007). A direct comparison of the distribution of cytokine levels showed no statistically significant differences between Groups 1 and 2 in any of the parameters. The correlation between cytokine levels in alopecia areata patients and the disease severity was analyzed in all patients without dividing them according to their atopic status due to the limited sample size in the subgroups. The levels of interleukins 1 alpha, 10, 21, 22, 23, 27 and tumor necrosis factor beta were positively correlated with alopecia severity, especially interleukin-23 (r = 0.372, p = 0.008); a negative correlation with SALT scores was observed for interleukin-2 (r = −0.457, p = 0.011) and interleukin-4 (r = −0.489, p = 0.006).Conclusion. The obtained results confirm the complex and systemic nature of immune abnormalities in alopecia areata. T helper 2 cytokines are clearly involved in the pathophysiologic process, with comorbid atopic diseases enhancing the T helper 2 response, potentially modulating interleukin-17A expression. The severe course of alopecia is associated with the activation of T helper 17 mediators (except for interleukin-17A) and a decrease in the levels of interleukins 2 and 4. The obtained data justify the appropriateness of personalized therapy that takes the atopic status and cytokine profile into account.